Literature DB >> 27072235

A rapid and sensitive method for EphB4 identification as a diagnostic and therapeutic biomarker in invasive breast cancer.

Mona Moshayedi, Farnaz Barneh, Shaghayegh Haghjooy-Javanmard, Hamid Mirmohammad Sadeghi, Nahid Eskandari, Ali Mohammad Sabzghabaee1.   

Abstract

BACKGROUND: In the roadmap to design diagnostic and therapeutic markers for breast cancer, EphB4 is of special interest due to its multiple roles in tumor initiation, progression and invasion. The aim of present study was to characterize a rapid and sensitive ELISA-based method to measure EphB4 level and its phosphorylation status following stimulation with its ligand, ephrinB2, in an invasive breast cancer cell line.
MATERIALS AND METHODS: MDA-MB-231 breast cancer cells were lysed and EphB4 level was measured using ELISA. EphB4 level was measured in sub- and post-confluent states in culture dishes. Receptor phosphorylation was also detected by ELISA assay, using various concentrations of pre-clustered ephrinB2 for 20 minutes.
RESULTS: Expression of EphB4 receptor was detected by ELISA in all samples. EphB4 level was significantly higher in post.confluent than sub.confluent cells. Phosphorylated receptor was also detectable with this method when cells were exogenously stimulated.
CONCLUSIONS: Quantitative data from ELISA manifested a difference between levels of EphB4 in two states of different invasive properties. Moreover, ELISA method may be considered rapid and sensitive enough to detect even low levels of total and phosphorylated EphB4 Cost-effectiveness of this method for the detection of differential expression of EphB4 proteins in clinics is also noticeable.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27072235     DOI: 10.4103/0973-1482.147254

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  1 in total

1.  The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages.

Authors:  Elnaz Shirmohammadi; Seyed-Esmaeil Sadat Ebrahimi; Amir Farshchi; Mona Salimi
Journal:  BMC Cancer       Date:  2020-09-03       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.